Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma.
about
Role of rituximab for first-line or relapsed aggressive B-cell lymphomaHigh-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive Non-Hodgkin Lymphoma (NHL) in adultsHigh-dose chemotherapy with autologous stem cell support for first-line treatment of aggressive non-Hodgkin lymphoma: a systematic review and meta-analysis based on individual patient dataHigh-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive Non-Hodgkin Lymphoma (NHL) in adultsThe use of serum deoxythymidine kinase as a prognostic marker, and in the monitoring of patients with non-Hodgkin's lymphomaThyroid lymphoma: recent advances in diagnosis and optimal management strategiesApproach to therapy of diffuse large B-cell lymphoma in the elderly: the International Society of Geriatric Oncology (SIOG) expert position commentaryInterpreting outcome data in hematological malignancies: a paradigm for clinical studiesAdvance and stagnation in the treatment of patients with lymphoma and myeloma: Analysis using population-based cancer registry data in Japan from 1993 to 2006.High dose CHOP: a phase II study of initial treatment in aggressive non-Hodgkin lymphoma. Cancer and Leukemia Group B 9351.Methyl-GAG, ifosfamide, methotrexate and etoposide (MIME) as salvage therapy for Hodgkin's disease and non-Hodgkin's lymphoma. The Swedish Lymphoma Study Group.Combined chemotherapy and granulocyte colony-stimulating factor (G-CSF) mobilise large numbers of peripheral blood progenitor cells in pretreated patients.Still's disease associated with Coxsackie infection and haemophagocytic syndromeIntermediate and high grade non Hodgkin's lymphoma in the elderly.Overcoming the limitations of chemotherapy in the treatment of B-cell non-Hodgkin's lymphomas--an approach using radiolabeled peptide ligands.The role of ifosfamide in the treatment of lymphomas.Historical review of lymphomas.Examining racial differences in diffuse large B-cell lymphoma presentation and survival.Disparities in the early adoption of chemoimmunotherapy for diffuse large B-cell lymphoma in the United States.Primary gastric lymphoma in clinical practice 1973-1992Adult T-cell leukemia-lymphoma with mediastinal involvement and an asymptomatic chronic phase.Current approaches to the treatment of advanced-stage non-Hodgkin's lymphomaA longitudinal study of non-medical determinants of adherence to R-CHOP therapy for diffuse large B-cell lymphoma: implication for survival.The impact of Fc-γ receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximabAcute lymphoblastic leukaemia of the L3 subtype in adults in the Northern health region of England 1983-99Adult T-cell leukemia/lymphoma not associated with human T-cell leukemia virus type IMicrovascular closure in malignant histiocytosisCurrent treatment options in aggressive lymphoma.Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvementA case of primary ovarian lymphoma with autoimmune hemolytic anemia achieving complete response with Rituximab-based combination chemotherapy.The need for a national cancer policy in MalawiEconomic assessment in the management of non-Hodgkin's lymphoma.Beta-2 microglobulin: a prognostic factor in diffuse aggressive non-Hodgkin's lymphomasTreatment of adult T-cell leukaemia-lymphoma with irinotecan hydrochloride (CPT-11). CPT-11 Study Group on Hematological Malignancy.A randomised comparison of a third-generation regimen (PACEBOM) with a standard regimen (CHOP) in patients with histologically aggressive non-Hodgkin's lymphoma: a British National Lymphoma Investigation reportComparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphoma.Pulmonary toxicity after granulocyte colony-stimulating factor-combined chemotherapy for non-Hodgkin's lymphoma.Novel treatment strategies for aggressive non-Hodgkin's lymphoma.A prospective study of surgery and adjuvant chemotherapy for primary gastric lymphoma stage II.CHOP-VP16 chemotherapy and involved field irradiation for high grade non-Hodgkin's lymphomas: a phase II multicentre study.
P2860
Q24236580-2364A887-103D-4ED1-A22C-9A7D488340BBQ24242089-1A986DEE-9B4D-4E0F-B49A-59C8FE2279C5Q24242447-AD3EC99C-0068-4316-BEEB-9F413F94A234Q24250490-64712EA7-5900-48D4-8537-773E7F2CC9FCQ24564929-3E2CEE9F-2A7D-4939-8CD9-6991E69CF320Q26827420-BCE32D14-C8A2-429D-A2E1-09A1BEC247C9Q28088365-81014188-DA92-495E-B9E5-A36FDD27FDA2Q30658847-8DE32196-4567-490D-ADA5-981ED48B0E98Q30895580-928095A0-A9AB-42B6-903A-3C90A21C4465Q33375173-948339FF-5626-4D59-A8C9-887D9F9F518BQ33407458-BC4D126D-E93C-4990-9402-23BA2F87269EQ33488145-938888A1-597B-4986-B5BA-175BEB6922ACQ33555897-C1973510-437E-4C2F-AB46-BED9EBA87065Q33604350-25139600-4D9B-4E57-B047-7C5B63A80AF1Q33607047-178F36D0-8E6F-46DE-9F43-176884664D01Q33735172-EE91A320-4C62-43DB-813C-677D3B9E3827Q33962044-0E51D973-6C01-4F33-BDB9-7EC75A16B888Q34117972-4CAB7413-AF38-462E-971B-74407F0B1C3FQ34138121-328AFB37-945D-437A-9ACB-F0E474C46E5FQ34408257-14452873-BA47-49A4-81E6-1B95ADE79584Q34699950-9ADB8B28-4C82-4B73-9CC6-3B3F00CF88FDQ34729695-BCC4A8D5-FA5A-4824-8361-35413C8E028DQ35494151-EDD1269E-7AE7-406C-AD58-2CADB0FDCBB6Q35525404-BF08E3BC-9E7A-4CDE-9CB1-EF4CCA002A77Q35586310-461313F8-C324-4B20-937E-651AFD5A77E4Q35612426-7D7908E6-53D6-41B9-B3B4-7F39E6D92A94Q35673876-B1D83E43-99A5-433E-BB19-E7B9AFB1FBE7Q35778926-08EC1181-0FC8-4287-8AF1-9218BF47517DQ35871945-D1339CAA-3AC0-4262-8843-3B59A3855E6CQ35931544-44AA5723-14CB-4759-85B0-58073CE365A3Q35938299-9302691D-3439-4B15-A798-6D5B2CB12728Q35967345-127A6128-10BC-4B1B-AA3A-34DC78614AACQ35976517-3010DABD-B568-4FDA-86AA-C578F04D2905Q36079661-C445EDD4-B0F9-46D9-9D45-ACB799210EF9Q36135553-93C52B9A-8F37-48E3-8187-4B64A7F909CAQ36160955-752F06C4-F975-4CC0-AB9C-B71779709D52Q36292887-20743878-DE4C-49FB-ABBA-624FDC0EEACAQ36429727-4F782562-4ADA-479B-BE89-CDDD483B7457Q36431532-439D496D-1DAB-43AB-B621-8A4C08BB4CDCQ36468032-DE5F8113-337B-4523-A36B-248393B65E25
P2860
Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma.
description
1976 nî lūn-bûn
@nan
1976年の論文
@ja
1976年論文
@yue
1976年論文
@zh-hant
1976年論文
@zh-hk
1976年論文
@zh-mo
1976年論文
@zh-tw
1976年论文
@wuu
1976年论文
@zh
1976年论文
@zh-cn
name
Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma.
@en
type
label
Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma.
@en
prefLabel
Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma.
@en
P2093
P1433
P1476
Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma.
@en
P2093
Gottlieb JA
Gutterman J
McKelvey EM
P304
P356
10.1002/1097-0142(197610)38:4<1484::AID-CNCR2820380407>3.0.CO;2-I
P407
P577
1976-10-01T00:00:00Z